What Happened?
Shares of telehealth company Hims & Hers Health (NYSE: HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According to SEC filings, CEO Andrew Dudum sold 660,000 shares for a total of approximately $33.4 million. The selling was not limited to the CEO, as Chief Medical Officer Patrick Carroll also sold 60,000 shares valued at around $3.2 million, while the company's chief commercial officer also recently parted with shares. Such significant stock sales by a company's top leadership can raise concerns among investors about the firm's future prospects. These transactions come at a challenging time for the telehealth company, which has recently faced legal pressure from drugmaker Novo Nordisk and a class-action lawsuit related to its compounded weight-loss drug offerings.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Hims & Hers Health’s shares are extremely volatile and have had 95 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock gained 34.9% on the news that Novo Nordisk announced plans to offer its weight loss drug Wegovy through Hims & Hers Health's platform, expanding access to one of its fastest-growing products. By partnering with a popular telehealth company, Novo could speed up Wegovy's adoption, leading to more prescriptions. For investors, the deal signals a clear strategy to expand distribution and grab more market share, a move that could also boost sales growth for Hims & Hers (HIMS).
Hims & Hers Health is up 91.4% since the beginning of the year, but at $48.23 per share, it is still trading 29.8% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $4,541.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
